دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
A Step Forward in Realizing the Promise of Genomic Medicine for Childhood Rhabdomyosarcoma.
Mascarenhas, Leo MD, MS 1,2,,
doi : 10.1200/JCO.21.01296
Volume 39(26) pgs. 2851-2972 September 10, 2021
What Is Neo? Chemoimmunotherapy in the Neoadjuvant Setting for Resectable Non-Small-Cell Lung Cancer.
Shu, Catherine A. MD 1,,; Cascone, Tina MD, PhD 2,
doi : 10.1200/JCO.21.01446
Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium.
Shern, Jack F. MD 1,2,; Selfe, Joanna PhD 3; Izquierdo, Elisa MD 4; Patidar, Rajesh MS 1; Chou, Hsien-Chao PhD 1; Song, Young K. PhD 1; Yohe, Marielle E. MD, PhD 2; Sindiri, Sivasish MS 1; Wei, Jun PhD 1; Wen, Xinyu MS 1; Rudzinski, Erin R. MD 5; Barkauskas, Donald A. PhD 6,7,; Lo, Tammy MPH 7; Hall, David MS 7; Linardic, Corinne M. MD, PhD 8,; Hughes, Debbie PhD 9; Jamal, Sabri MSc 4; Jenney, Meriel MD 10; Chisholm, Julia MD 11,; Brown, Rebecca MD 3,12; Jones, Kristine PhD 13; Hicks, Belynda PhD 13,; Angelini, Paola MD 11; George, Sally MD 9,11; Chesler, Louis MD 9; Hubank, Michael MD 4,; Kelsey, Anna MD 14,; Gatz, Susanne A. MD 3,15,; Skapek, Stephen X. MD 16; Hawkins, Douglas S. MD 17,; Shipley, Janet M. PhD 3; Khan, Javed MD 1,
doi : 10.1200/JCO.20.03060
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
Rothschild, Sacha I. MD, PhD 1,,; Zippelius, Alfred MD 1,; Eboulet, Eric I. PhD 2; Savic Prince, Spasenija MD 3,; Betticher, Daniel MD 4,; Bettini, Adrienne MD 4,; Fruh, Martin MD 5,6,; Joerger, Markus MD, PhD 5,; Lardinois, Didier MD 7; Gelpke, Hans MD 8; Mauti, Laetitia A. MD, PhD 9,; Britschgi, Christian MD, PhD 10,; Weder, Walter MD 11,; Peters, Solange MD, PhD 12,; Mark, Michael MD 13,; Cathomas, Richard MD 13,; Ochsenbein, Adrian F. MD 6,; Janthur, Wolf-Dieter MD 14,; Waibel, Christine MD 15; Mach, Nicolas MD 16,; Froesch, Patrizia MD 17,; Buess, Martin MD, PhD 18; Bohanes, Pierre MD 19,; Godar, Gilles MSc 2; Rusterholz, Corinne PhD 2,; Gonzalez, Michel MD 20; Pless, Miklos MD 9,; for the Swiss Group for Clinical Cancer Research (SAKK)
doi : 10.1200/JCO.21.00276
Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis.
Mascarenhas, John MD 1,,; Komrokji, Rami S. MD 2,; Palandri, Francesca MD 3; Martino, Bruno MD 4; Niederwieser, Dietger MD, PhD 5,; Reiter, Andreas MD 6,; Scott, Bart L. MD 7,; Baer, Maria R. MD 8,; Hoffman, Ronald MD 1,; Odenike, Olatoyosi MD 9,; Vannucchi, Alessandro M. MD 10,; Bussolari, Jacqueline PhD 11,; Zhu, Eugene PhD 11,; Rose, Esther MD 11,; Sherman, Laurie BSN 12,; Dougherty, Souria BS, MBA 12,; Sun, Libo PhD 12,; Huang, Fei PhD 12,; Wan, Ying PhD 12,; Feller, Faye M. MD 12,; Rizo, Aleksandra MD, PhD 12,; Kiladjian, Jean-Jacques MD, PhD 13,
doi : 10.1200/JCO.20.02864
Development and Validation of a Simulation Model-Based Clinical Decision Tool: Identifying Patients Where 21-Gene Recurrence Score Testing May Change Decisions.
Jayasekera, Jinani PhD 1,2,; Sparano, Joseph A. MD 3,; O'Neill, Suzanne PhD 1,2,; Chandler, Young PhD 1,2; Isaacs, Claudine MD 1,2,; Kurian, Allison W. MD, MSc 4,; Kushi, Lawrence PhD 5; Schechter, Clyde B. MD, MA 6; Mandelblatt, Jeanne MD, MPH 1,2
doi : 10.1200/JCO.21.00651
PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer.
Kang, Yoon-Koo MD 1,,; Yook, Jeong Hwan MD 2; Park, Young-Kyu MD 3; Lee, Jong Seok MD 4; Kim, Jong Seok MD 5; Kim, Jin Young MD 6; Ryu, Min-Hee MD 1,; Rha, Sun Young MD 7,; Chung, Ik Joo MD 8; Kim, In-Ho MD 9; Oh, Sang Cheul MD 10; Park, Young Soo MD 11; Son, Taeil MD 12; Jung, Mi Ran MD 3; Heo, Mi Hwa MD 6; Kim, Hark Kyun MD 5; Park, ChoHyun MD 13; Yoo, Chang Hak MD 14; Choi, Jin-Hyuk MD 15; Zang, Dae Young MD 16; Jang, You Jin MD 17; Sul, Ji Young MD 18; Kim, Jong Gwang MD 19; Kim, Beom Su MD 2; Beom, Seung-Hoon MD 7; Cho, Sang Hee MD 8; Ryu, Seung Wan MD 20; Kook, Myeong-Cherl MD 5; Ryoo, Baek-Yeol MD 1; Kim, Hyun Ki MD 21; Yoo, Moon-Won MD 2; Lee, Nam Su MD 22; Lee, Sang Ho MD 23; Kim, Gyunji MD 24,; Lee, YeonJu PharmD 24,; Lee, Jee Hyun MSc 24,; Noh, Sung Hoon MD 25
doi : 10.1200/JCO.20.02914
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.
Diab, Adi MD 1,,; Tykodi, Scott S. MD, PhD 2,; Daniels, Gregory A. MD, PhD 3,; Maio, Michele MD 4,; Curti, Brendan D. MD 5,; Lewis, Karl D. MD 6,; Jang, Sekwon MD 7,; Kalinka, Ewa MD, PhD 8,; Puzanov, Igor MD, MSci 9,; Spira, Alexander I. MD, PhD 10,; Cho, Daniel C. MD 11,; Guan, Shanhong PhD 12,; Puente, Erika MD 12,; Nguyen, Tuan PhD 12,; Hoch, Ute PhD 12,; Currie, Sue L. PhD 12,; Lin, Wei MD 12,; Tagliaferri, Mary A. MD 12,; Zalevsky, Jonathan PhD 12,; Sznol, Mario MD 13,; Hurwitz, Michael E. MD, PhD 13,
doi : 10.1200/JCO.21.00675
Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer.
Sperger, Jamie M. PhD 1; Emamekhoo, Hamid MD 1,; McKay, Rana R. MD 2,; Stahlfeld, Charlotte N. BS 1; Singh, Anupama PhD 1; Chen, Xinyi E. BS 3; Kwak, Lucia MS 4; Gilsdorf, Cole S. BS 1; Wolfe, Serena K. BS 1; Wei, Xiao X. MD 4,; Silver, Rebecca BS 4,; Zhang, Zhenwei MD, PhD 4; Morris, Michael J. MD 5,; Bubley, Glenn MD 6; Feng, Felix Y. MD 7,8,9,; Scher, Howard I. MD 5,; Rathkopf, Dana MD 5,; Dehm, Scott M. PhD 10,; Choueiri, Toni K. MD 4,; Halabi, Susan PhD 11,12,; Armstrong, Andrew J. MD 11,; Wyatt, Alexander W. PhD 3,; Taplin, Mary-Ellen MD 4,; Zhao, Shuang G. MD 1,13,14,; Lang, Joshua M. MD 1,15,,
doi : 10.1200/JCO.21.00169
Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial.
D'Amico, Anthony V. MD, PhD 1,; Xie, Wanling MS 2; McMahon, Elizabeth RN 1; Loffredo, Marian RN, OCN 1; Medeiros, Shana 1; Joseph, David MD 3; Denham, Jim MD 4; Kumar, Parvesh MD 5; Bubley, Glenn MD 6; Sullivan, Molly MD 7,; Hellwig, Richard MD 8; Carlos Vera, Juan MD 9; Freter, Rolf MD, PhD 10; Jeffrey Baker, W. MD 11; Wong, Jeffrey Y. MD 12,; Renshaw, Andrew A. MD 13; Kantoff, Philip W. MD 14,
doi : 10.1200/JCO.21.00596
US Trends in Opioid Access Among Patients With Poor Prognosis Cancer Near the End-of-Life.
Enzinger, Andrea C. MD 1,,; Ghosh, Kaushik PhD 2; Keating, Nancy L. MD, MPH 3,4; Cutler, David M. PhD 2,3,5,6,; Landrum, Mary Beth PhD 3; Wright, Alexi A. MD, MPH 1,
doi : 10.1200/JCO.21.00476
Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update.
Tung, Nadine M. MD 1,; Zakalik, Dana MD 2; Somerfield, Mark R. PhD 3; for the Hereditary Breast Cancer Guideline Expert Panel
doi : 10.1200/JCO.21.01532
Case for Focused Bereavement Education in Oncology Training.
Sedhom, Ramy MD; Gupta, Arjun MD; Von Roenn, Jamie MD
doi : 10.1200/JCO.21.01135
Regarding the Appropriate Target and Duration of Chemoprevention in Breast Cancer.
Suemasu, Takahito MD; Shimomura, Akihiko MD, PhD; Shimizu, Chikako MD, PhD; Hashimoto, Kazuki MD; Kitagawa, Dai MD, PhD
doi : 10.1200/JCO.21.01060
Reply to T. Suemasu et al.
Eriksson, Mikael PhD; Czene, Kamila PhD; Hall, Per PhD, MD
doi : 10.1200/JCO.21.01166
Metastatic Prostate Cancer: In Search of More Granularity.
Tewari, Alok K. MD, PhD; Gillessen, Silke MD; Sweeney, Christopher J. MBBS
doi : 10.1200/JCO.21.00643
Reply to A. K. Tewari et al.
Talcott, James A. MD, SM; Virgo, Katherine S. PhD, MBA
doi : 10.1200/JCO.21.00753
Do the Survival Data of Primary Tumor Resection Provide Sufficient Data Without Considering the Tumor Sidedness, Predictive Biomarkers, and Biologic Agents?.
Bozkurt Duman, Berna MD; Cil, Timucin MD
doi : 10.1200/JCO.21.00560
